Apple Advances Health Tech Innovation
Apple has announced a significant update to its Apple Watch blood oxygen monitoring capability. The tech giant is introducing a redesigned feature for select models—including Series 8, Series 10, and Apple Watch Ultra—overcoming previous import restrictions enforced by the International Trade Commission (ITC).
Regulatory Adaptation and Feature Redesign
Under a recent U.S. Customs ruling, Apple is now authorized to import these devices with the modified blood oxygen feature, a move that circumvents the ITC ban established in early 2024. The revised functionality shifts blood oxygen data processing to the paired iPhone, with results accessible through the Respiratory section of the Health app. As a consequence, users will need to consult their iPhone to review their health metrics, as direct watch-based access is no longer available.
Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram
Legal Context and Ongoing Disputes
This development follows a contentious legal battle with medical device maker Masimo. In 2023, Masimo secured a victory at the ITC, which led to the removal of the original blood oxygen monitoring feature from Apple Watches due to alleged patent infringement. Apple has since counter-sued, alleging that Masimo replicated features from its smartwatch. The recent update, enabled by a Customs ruling, only applies to devices sold post-ban, while earlier purchases or units sold outside the U.S. remain unaffected.
Implications for the Industry
Apple’s move not only underscores its commitment to innovation within regulatory constraints but also signals a strategic response to competitive and legal pressures. By recalibrating its product capabilities, Apple reaffirms its position as a technological leader capable of navigating complex international trade and intellectual property challenges.
